continu capit healthi end market
maintain buy rate agil along tp
deriv tp base forward price-to-earnings
multipl adjust ep
provid upsid potenti
estim top line growth
estim base follow factor strong
growth revenu improv oper margin strong
growth pharma chemic market strong
growth revenu china acquisit prozym
ultra scientif asset strengthen portfolio
agil deliv strong perform quarter led
growth china pharma chemic end
market agil revenu increas
agil deliv adjust oper margin
increas bp prior-year period
gaap ep increas non-gaap
ep increas
life scienc appli market group lsag revenu
grew due strength
chemic energi pharma end market
agil crosslab group acg revenu grew
servic consum saw strong
growth across end market geographi
diagnost genom group dgg revenu grew
due strength genom china
compani name inc tickerastock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc| octob
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
pharma market revenu grew core
basi due strength across busi group strong
perform mass spectrometri cell analysi crosslab
consum servic genom
chemic market revenu increas due
strength spectroscopi gc crosslab consum
inc announc complet
acquisit prozym inc lead provid
glycan reagent kit standard acquisit expand
agil portfolio biopharma consum
announc complet
acquisit busi asset ultra scientif
inc lead provid chemic standard certifi
agil expect revenu grow rang
ep expect rang
current price-to-earnings averag price-to-earnings
due growth ep perform stock
price-to-earnings fallen
trail near
expect forward price-to-earnings multipl
recommend buy rate agil base
perform period acquisit made
period expect top-lin
revenu grow
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date oct ex-dividend date oct last split factor new per last split date inform agil technolog inc| octob
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper interest incom interest incom incom incom minor net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc| octob
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item agil inc| octob
net cash inflow oper activ period compar cash
inflow agil paid variabl incent pay program
net cash use invest activ period compar
increas properti plant equip relat capac expans
nucleic acid solut facil agil invest acquisit five busi
net cash use financ activ period compar
depreciation- defer incom taxes- oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc| octob
agil deliv strong perform quarter due growth
revenu earn led china global pharma chemic
increas
due
strong growth
pharma chemic
china
agil revenu increas compar
due strong growth pharma chemic china
net product revenu increas compar
servic revenu increas
compar
increas
due higher
sale volum
off-set increas
wage variabl pay
unfavor
cog increas compar
gross margin increas compar
increas reflect higher sale volum favor busi mix off-set
increas wage variabl pay unfavor currenc movement
 expens increas compar
research develop expens increas due increas
program spend new product relat busi addit
higher wage variabl pay unfavor currenc movement addit
expens relat acquir busi compar spend
period last year
sg expens increas compar
increas sell gener administr expens due
higher wage variabl pay higher commiss higher acquisit
integr cost unfavor currenc movement
oper margin increas compar
oper margin impact higher gross margin lower acquisit
integr cost lower amort expens off-set increas wage
recent acquisit unfavor currenc movement
gaap ep increas
compar
net revenu
compar
effect tax rate compar
incom tax expens incom
compar interest incom compar
interest expens compar
net incom increas compar
ep increas compar
non-gaap ep increas
agil gener oper cash flow invest
paid dividend repurchas share
net revenu period increas
compar foreign currenc movement favor
impact revenu ppt compar prior year period
net product revenu period increas
compar servic revenu
period increas compar
cog increas period compar
gross margin period increas ppt
compar increas due higher
sale volum favor busi mix lower manufactur materi cost
lower amort expens intang asset partial off-set increas
wage variabl pay inventori charg
 expens period increas
compar expens increas due increas program
spend new product relat busi addit higher
wage variabl pay unfavor currenc movement addit
expens relat acquir busi
sg expens period increas
compar increas due higher wage
compens expens higher transform initi cost unfavor
oper margin period rel flat
compar oper margin impact higher gross margin
lower acquisit integr cost lower amort expens off-set
increas wage variabl pay higher transform initi cost
addit expens relat recent acquisit unfavor currenc
incom period compar
interest incom period increas
compar interest expens period
declin compar
effect tax rate period increas
compar incom tax expens
period effect tax rate result provis
incom tax impact discret charg relat
enact tax act
net incom period declin compar
net incom due increas tax rate ep
month period compar
sg expens
compar
net incom
compar net incom
due
increas tax rate
revenu geographi
 contribut total revenu
europ contribut total revenu
asia pacif region contribut total revenu
china busi grew
quarter
due double-digit
growth two largest
chemic
contribut total
revenu
europ flat growth
china busi grew quarter due double-digit growth
two largest end-market pharma chemic
busi also strong america rest asia outsid china
two region deliv healthi high single-digit growth europ
flat quarter
revenu type instrument revenu quarter contribut
total revenu consum servic informat contribut total
revenu
revenu major market analyt laboratori contribut total
revenu dx clinic market contribut total revenu
revenu end-market
agil strong growth quarter due gain pharma
revenu grew
core basi due
strength across
busi group
strong perform
consum
servic genom
y/i core basi
pharma revenu grew core basi due strength
across busi group strong perform mass spectrometri
cell analysi crosslab consum servic genom
growth remain robust bio-pharma small molecul market
academia government revenu increas due demand cell
analysi molecular spectroscopi icp/m crosslab servic china
rest asia deliv double-digit growth end-market
environment forens revenu flat quarter forens
growth off-set expect temporari slow instrument sale
china environment
chemic forens clinic govern inc| octob
revenu end-market
food revenu declin strong growth america off-set
declin europ china instrument sale also
quarter
chemic revenu increas due strength
spectroscopi gc crosslab consum servic geograph
strong gain china europ lead overal global growth
diagnost clinic end market revenu grew y/i core basi
led strength reagent partnership genom busi off-set
continu challeng pain manag market
revenu increas
due strength
consum
compar
life scienc appli market group lsag
life scienc appli market busi provid application-focus
solut includ instrument softwar enabl custom
identifi quantifi analyz physic biolog properti
substanc product well enabl custom clinic life
scienc research area interrog sampl molecular cellular
lsag revenu increas compar
total revenu period increas
compar foreign currenc movement
overal favor impact revenu ppt period ppt
period
geograph revenu increas america currenc
impact decreas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
life scienc appli market group lsag
revenu increas america ppt favor currenc
impact increas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
month period
quarter spectroscopi liquid chromatographi mass
spectrometri cell analysi solid growth help strong product
offer period growth due liquid
chromatographi mass spectrometri spectroscopi ga chromatographi
end market perform led growth chemic
energi market pharmaceut market continu demonstr solid
growth life scienc research food market declin due delay
revenu relat reorgan sever government agenc
period chemic energi pharmaceut
market led growth fuel new product offer liquid
chromatographi mass spectrometri spectroscopi
quarter
spectrometri cell
analysi solid growth
help strong product
oper margin increas compar
oper margin period increas
compar
agil releas agil seahors xf real-tim atp rate assay kit
new unmatch product enabl biologist enhanc
understand live-cel function real-tim
agil close acquisit genohm develop highli differenti
softwar solut sampl track lab manag
revenu increas
compar
column remarket
instrument
impact within agil
agil crosslab busi span entir lab extens consum
servic portfolio design improv custom outcom
product categori consum includ gc lc column sampl
prepar product custom chemistri larg select laboratori
instrument suppli servic includ start-up oper train
complianc support softwar servic well asset manag
consult servic help increas custom product
agil crosslab group revenu increas
compar total revenu period
increas compar
foreign currenc movement overal favor impact revenu
ppt ppt period
geograph revenu increas america currenc
impact increas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
revenu increas america currenc impact
increas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
remarket instrument highest revenu growth impact
within agil crosslab busi
period complianc servic multi-vendor
servic prevent mainten well lc gc column
highest revenu growth impact within agil crosslab busi
oper margin flat compar previou year
quarter oper margin period increas
compar
period major end market
segment contribut strong revenu growth particular end
market stood servic busi consum busi
agil acquir
busi asset ultra
provid chemic
standard certifi
agil acquir busi asset ultra scientif lead provid
chemic standard certifi refer materi also acquir
prozym lead provid biopharma consum glycan analysi
agil open new logist hub shanghai enabl faster deliveri
part suppli consum lab china
compar
diagnost genom group dgg
diagnost genom busi includ genom nucleic acid contract
manufactur patholog companion diagnost reagent
partnership busi compris five area activ provid solut
includ reagent instrument softwar consum enabl
custom clinic life scienc research area interrog sampl
cellular molecular level
dcg revenu increas compar
total revenu period increas
compar foreign currenc movement
period overal favor impact
revenu ppt ppt respect
geograph revenu increas america currenc
impact increas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
revenu increas america currenc impact
increas europ ppt favor currenc impact
increas asia pacif ppt favor currenc impact
period
diagnost genom group dgg
asia pacif particularli china america led revenu
growth genom busi sure select target enrich
portfolio strength japan reagent partnership busi
europ flat due lower shipment volum genom busi
period america europ saw growth
genom patholog busi target enrich portfolio
omni platform respect asia pacif grew slower due lower
volum patholog busi china japan
growth led revenu growth next gener
solut portfolio offer within genom busi mainli due
sure select target enrich agil continu see momentum
reagent partnership busi strong demand bioanalyz
consum portfolio end market diagnost clinic research
remain strong continu growth driven age popul
period improv perform due
strength target enrich portfolio genom busi good
revenu growth reagent partnership busi
oper margin increas compar
oper margin period declin
compar
burn dx receiv china fda approv human lung cancer
detect kit use agil sureselect reagent
receiv fda approv onpattro first of-
its-kind target rna base therapi treat rare diseas march
agil nasd busi agre becom alnylam commerci supplier
onpattro api
america led
revenu growth
genom busi
sure select
portfolio strength
japan reagent
china fda approv
human lung cancer
detect kit
agil recent action profit growth plan includ
deliv agil agil initi
multi-year program increas effici custom focu
oper margin continu expand bp
portfolio invest go-to-market capabl
agil acquir ultra scientif lead provid chemic standard
certifi refer materi
agil acquir prozym lead provid biopharma
consum glycan analysi strengthen agil offer
applic space essenti develop biotherapeut
digit channel order consum grow record pace
agil achiev mileston exceed order volum
agil open new logist hub shanghai hub first five
forward stock locat enabl faster deliveri part supplier
consum laboratori china
agil announc new version openlab cd chemstat edit
chromatographi data system enabl laboratori export file
allotrop data format adf adf emerg standard develop
consortium pharmaceut compani standard
common data format lab abl readili transfer share
receiv expand fda approv cervic cancer
provid biopharma
consum glycan
fda approv cervic
revenu expect
grow rang
revenu growth mid-point core growth
ep expect
rang
oper margin mid-point adjust
keysight bill classifi incom
revenu growth mid-point core growth
stock base compens
net interest expens plu incom includ
keysight bill
depreci capital-expenditure oper
return dividend non-gaap tax rate expect
agil deliv anoth strong quarter robust revenu earn
growth led china global pharma chemic end
market agil revenu increas ep
increas non-gaap ep increas
strong revenu
earn growth led
china global
pharma chemic
agil also achiev consecut quarter improv y/i core oper
margin agil deliv adjust oper margin
increas bp prior-year period
life scienc appli market group lsag revenu grew
due strength chemic energi pharma end
market lsag oper margin quarter
agil crosslab group acg revenu grew
servic consum saw strong growth across end market
geographi acg oper margin quarter
diagnost genom group dgg revenu grew
due strength genom china dgg oper margin
quarter
agil repurchas share paid dividend invest
 inc announc complet
acquisit prozym inc lead provid glycan reagent kit
standard acquisit expand agil portfolio biopharma
announc complet acquisit
busi asset ultra scientif inc lead provid chemic standard
certifi refer materi
agil continu capit healthi end market deliv anoth
strong quarter ytd stock perform agil compar
 roa roi roe ttm basi
inc announc
complet
acquisit prozym
glycan reagent kit
standard
non- reconcili
non- reconcili
non- reconcili
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas ttm basi compar due declin cog
revenu growth increas ttm basi compar
net margin reduc ttm basi compar due increas tax
ep growth reduc ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth agil inc| octob
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale agil inc| octob
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale agil inc| octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item agil technolog inc| octob
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas investment- sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc| octob
current price-to-earnings averag price-to-earnings due growth ep perform
stock price-to-earnings fallen trail near
expect forward price-to-earnings multipl
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form michael paul boon institut holdersholdershar report outvaluepric row associ vanguard group inc fmr oppenheim fund shaw co state mutual automobil insur primecap manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market price row mid cap growth vanguard price row price row valu spdr etf vanguard institut fund-institut vanguard growth fidel ishar inc| octob
develop complet acquisit prozymeaugust inc announc complet acquisit ofprozym inc lead provid glycan reagent kit standard acquisit expand agil portfolio biopharma consum complet acquisit ultra scientif assetsjuli inc announc complet acquisit busi asset ofultra scientif inc lead provid chemic standard certifi refer materi complet acquisit advanc analyt inc may inc announc complet acquisit ofadvanc analyt inc aati provid capillari electrophoresis-bas ce solut fully-autom analysi rang molecul cash agil sign agreement acquir asset young scientif co ltd may inc announc sign definit agreement acquir theagilent-rel busi young scientif co ltd yi scientif yi scientif lead distributor analyt scientif instrument insouth koreaand long-tim distributor ofagilentinstru servic inc| octob
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
agil
compar
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit agil inc| octob
consensu view analyst trend stock
forecast agil
forward price-to-earnings
compar
 avgfive-year growth forecast usdgrowth high day day day estim comparisonaindustri avg avgprice/earn yield inc| octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr agil technolog inc| octob
price target summarycrispidea suissedowngradeneutralund robinson co downgrademarket performrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext agil inc| octob
incom statement
result revenu
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price movement show upward trend period surg
averag volum trade quarter stock gave return last
stock price show huge fluctuat past one year dip juli
stock given return last one year rang stock
stock price show uptrend last three year gave return last three year
stock gave huge return past due perform past
agil deliv strong result due growth china pharma chemic energi market
agil complet acquisit prozym ultra scientif asset strengthen portfolio
success execut strategi recommend buy rate stock base perform
product portfolio maintain tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
